Tanaka Yuta, Kurasawa Osamu, Yokota Akihiro, Klein Michael G, Saito Bunnai, Matsumoto Shigemitsu, Okaniwa Masanori, Ambrus-Aikelin Geza, Uchiyama Noriko, Morishita Daisuke, Kimura Hiromichi, Imamura Shinichi
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Department of Structural Biology, Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States.
ACS Med Chem Lett. 2020 Jul 30;11(8):1645-1652. doi: 10.1021/acsmedchemlett.0c00331. eCollection 2020 Aug 13.
Deoxyhypusine synthase (DHPS) is the primary enzyme responsible for the hypusine modification and, thereby, activation of the eukaryotic translation initiation factor 5A (eIF5A), which is key in regulating the protein translation processes associated with tumor proliferation. Although DHPS inhibitors could be a promising therapeutic option for treating cancer, only a few studies reported druglike compounds with this inhibition property. Thus, in this work, we designed and synthesized a new chemical series possessing fused ring scaffolds designed from high-throughput screening hit compounds, discovering a 5,6-dihydrothieno[2,3-]pyridine derivative () with potent inhibitory activity; furthermore, the X-ray crystallographic analysis of the DHPS complex with demonstrated a distinct allosteric binding mode compared to a previously reported inhibitor. These findings could be significantly useful in the functional analysis of conformational changes in DHPS as well as the structure-based design of allosteric inhibitors.
脱氧hypusine合酶(DHPS)是负责hypusine修饰从而激活真核翻译起始因子5A(eIF5A)的主要酶,而eIF5A在调节与肿瘤增殖相关的蛋白质翻译过程中起关键作用。尽管DHPS抑制剂可能是治疗癌症的一种有前景的治疗选择,但只有少数研究报道了具有这种抑制特性的类药物化合物。因此,在这项工作中,我们设计并合成了一个新的化学系列,该系列具有基于高通量筛选命中化合物设计的稠环支架,发现了一种具有强效抑制活性的5,6-二氢噻吩并[2,3-]吡啶衍生物();此外,与之前报道的抑制剂相比,DHPS与该衍生物复合物的X射线晶体学分析显示出一种独特的变构结合模式。这些发现对于DHPS构象变化的功能分析以及变构抑制剂的基于结构的设计可能具有重要意义。